{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:43:52Z","timestamp":1787319832570,"version":"build-2736575974"},"reference-count":23,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive. We have shown that immunomodulatory drugs (IMiDs) exert anti-MM activity via destabilization of MCT1 and CD147. In this study, cell samples of 654 patients with MM who received lenalidomide (n = 455), thalidomide (n = 98), or bortezomib (n = 101) maintenance were assessed by gene expression profiling and RNA sequencing, followed by correlation of MCT1 and CD147 expression with data for progression-free survival (PFS) and overall survival (OS). Patients with high expression levels of MCT1 showed significantly reduced PFS (31.9 months vs 48.2 months in MCT1high vs MCT1low; P = .03) and OS (75.9 months vs not reached [NR] in MCT1high vs MCT1low; P = .001) in cases with lenalidomide maintenance, whereas MCT1 expression had no significant impact on PFS or OS in cases with bortezomib maintenance. We validated the predictive role of MCT1 for IMiD-based maintenance in an independent cohort of patients who received thalidomide (OS, 83.6 months vs NR in MCT1high vs MCT1low; P = .03). Functional validation showed that MCT1 overexpression in human MM cell lines significantly reduced the efficacy of lenalidomide, whereas no change was observed with bortezomib treatment, either in vitro or in a MM xenograft model. Our findings have established MCT1 expression as a predictive marker for response to lenalidomide-based maintenance in patients with MM.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005532","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T18:51:14Z","timestamp":1636743074000},"page":"515-520","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma"],"prefix":"10.1182","volume":"6","author":[{"given":"Jacob","family":"Stroh","sequence":"first","affiliation":[{"name":"Department of Medicine III, Klinikum rechts der Isar, and"},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2771-712X","authenticated-orcid":false,"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunology, Myeloma Center Brussels, and"},{"name":"Labor f\u00fcr Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heider","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Klinikum rechts der Isar, and"},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Ludwigs Maximilians University, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8433-9452","authenticated-orcid":false,"given":"Ruth","family":"Eichner","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Klinikum rechts der Isar, and"},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schick","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9-Universit\u00e4tsmedizin, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Slawska","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Klinikum rechts der Isar, and"},{"name":"Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9-Universit\u00e4tsmedizin, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Emde-Rajaratnam","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunology, Myeloma Center Brussels, and"},{"name":"Labor f\u00fcr Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Salwender","sequence":"additional","affiliation":[{"name":"Asklepios Tumorzentrum Hamburg, Hamburg, Germany;"},{"name":"AK Altona, Hamburg, Germany;"},{"name":"AK St. Georg, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, and"},{"name":"National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"Department of Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, and"},{"name":"Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9-Universit\u00e4tsmedizin, Berlin, Germany;"},{"name":"German Cancer Consortium (DKTK), Heidelberg, Germany;"},{"name":"German Cancer Research Center (DKFZ), Heidelberg, Germany; and"},{"name":"Max-Delbr\u00fcck Center for Molecular Medicine, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunology, Myeloma Center Brussels, and"},{"name":"Labor f\u00fcr Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Klinikum rechts der Isar, and"},{"name":"TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany;"},{"name":"German Cancer Consortium (DKTK), Heidelberg, Germany;"},{"name":"German Cancer Research Center (DKFZ), Heidelberg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"5","key":"2022011816243754500_B1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol."},{"issue":"14","key":"2022011816243754500_B2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol."},{"issue":"19","key":"2022011816243754500_B3","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"2022011816243754500_B4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"issue":"19","key":"2022011816243754500_B5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med."},{"issue":"10","key":"2022011816243754500_B6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med."},{"issue":"7","key":"2022011816243754500_B7","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt","year":"2020","journal-title":"Leukemia."},{"issue":"29","key":"2022011816243754500_B8","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022011816243754500_B9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nat Med."},{"issue":"6","key":"2022011816243754500_B10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.molcel.2020.12.046","article-title":"The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma","volume":"81","author":"Heider","year":"2021","journal-title":"Mol Cell."},{"issue":"6168","key":"2022011816243754500_B11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science."},{"issue":"6168","key":"2022011816243754500_B12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science."},{"issue":"15","key":"2022011816243754500_B13","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","article-title":"CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression","volume":"19","author":"Kirk","year":"2000","journal-title":"EMBO J."},{"issue":"3","key":"2022011816243754500_B14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.yexmp.2007.08.014","article-title":"CD147 immunoglobulin superfamily receptor function and role in pathology","volume":"83","author":"Iacono","year":"2007","journal-title":"Exp Mol Pathol."},{"issue":"19","key":"2022011816243754500_B15","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.4161\/cc.26193","article-title":"CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells","volume":"12","author":"Walters","year":"2013","journal-title":"Cell Cycle."},{"issue":"10","key":"2022011816243754500_B16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/leu.2012.91","article-title":"Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation","volume":"26","author":"Arendt","year":"2012","journal-title":"Leukemia."},{"issue":"6","key":"2022011816243754500_B17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nm.3867","article-title":"The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells","volume":"21","author":"Zhu","year":"2015","journal-title":"Nat Med."},{"key":"2022011816243754500_B18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-7865-6_7","article-title":"RNA-sequencing from low-input material in multiple myeloma for application in clinical routine","volume":"1792","author":"Seckinger","year":"2018","journal-title":"Methods Mol Biol."},{"issue":"3","key":"2022011816243754500_B19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell."},{"key":"2022011816243754500_B20","first-page":"108","author":"Warren","year":"2007"},{"key":"2022011816243754500_B21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3389\/fimmu.2018.01676","article-title":"CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance","volume":"9","author":"Seckinger","year":"2018","journal-title":"Front Immunol."},{"issue":"12","key":"2022011816243754500_B22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3740","article-title":"Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis","volume":"20","author":"Baumann","year":"2014","journal-title":"Nat Med."},{"issue":"45","key":"2022011816243754500_B23","doi-asserted-by":"crossref","first-page":"16245","DOI":"10.1073\/pnas.0504419102","article-title":"Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia","volume":"102","author":"Deora","year":"2005","journal-title":"Proc Natl Acad Sci USA."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/515\/1860439\/advancesadv2021005532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/515\/1860439\/advancesadv2021005532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T15:43:59Z","timestamp":1642520639000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/2\/515\/477959\/MCT1-is-a-predictive-marker-for-lenalidomide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005532","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}